CD20 POSITIVE
Clinical trials for CD20 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CD20 POSITIVE trials appear
Sign up with your email to follow new studies for CD20 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise against tough blood cancer
Disease control OngoingThis study tests a two-drug combination (ibrutinib and rituximab) in people with mantle cell lymphoma that has returned or not responded to treatment, or in older adults newly diagnosed. The goal is to shrink or control the cancer. About 113 participants will receive the drugs to…
Matched conditions: CD20 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis phase II trial is testing two oral drugs, venetoclax and acalabrutinib, in 32 people with mantle cell lymphoma that has returned or not responded to prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Both drugs work by blocking …
Matched conditions: CD20 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New cocktail targets tough lymphoma: carfilzomib joins R-ICE in early trial
Disease control OngoingThis early-phase trial tested adding carfilzomib to a standard chemotherapy regimen (R-ICE) for adults with diffuse large B-cell lymphoma that returned or didn't respond to prior treatment. The main goals were to find the safest dose of carfilzomib and see how well the combinatio…
Matched conditions: CD20 POSITIVE
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…
Matched conditions: CD20 POSITIVE
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:34 UTC